Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 56 publications
Nilotinib in chronic myeloid leukemia: clinical value, real-world challenges, and the potential of nilotinib tablets to improve therapeutic outcomes.
Journal: Expert review of hematology
Published: August 12, 2026
Erratum: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 30, 2026
Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 02, 2026
Single agent selinexor is active in patients with myelofibrosis refractory or intolerant to JAK inhibitors.
Journal: Blood cancer journal
Published: April 30, 2026
Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy.
Journal: HemaSphere
Published: February 06, 2026
Current treatments, practical management, and emerging investigational therapies for myelofibrosis.
Journal: Expert review of hematology
Published: December 14, 2025
Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase.
Journal: Hematology (Amsterdam, Netherlands)
Published: October 07, 2025
Mutant calreticulin-directed immunotherapies in myeloproliferative neoplasms.
Journal: Blood neoplasia
Published: September 03, 2025
Treatment Patterns and Outcomes of Patients With Myelodysplastic Syndrome (MDS) by IPSS-R Scores at Academic Cancer Centers.
Journal: Advances in hematology
Published: March 10, 2025
Last Updated: 09/26/2026